Icaritin |
Catalog No.GC38096 |
Icaritin is a prenylflavonoid derivative obtained from the Epimedium genus.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 118525-40-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
HCC cell line SMMC-7721 and monocyte THP-1 |
Preparation Method |
Cells were treated with 10 µM (SMMC-7721) or indicated concentrations (THP-1) of Icaritin for 1 h, followed by 50 ng/mL TNF-α for 24 h or 48 h. |
Reaction Conditions |
0-20uM Icaritin for 1h |
Applications |
Icaritin is able to inhibit PD-L1 expression in both immune cells and cancer cells, leading to its combinational in-vivo efficacy with anti-PD1 antibody in inhibition of malignant tumor growth, because Icaritin functions through immune modulation, particularly immune cells with myeloid lineage, so that THP-1 cell line was employed along with SMMC-7221 cell line. |
Animal experiment [2]: | |
Animal models |
C57BL/6 mice (6-8 weeks old, male and female) |
Preparation Method |
For the IL-2 in combination with icaritin treatment experiments, 35 mg/kg body weight of icaritin was gavage administered from day 3 to day 21 after the inoculation of B16F10 tumor cells. |
Dosage form |
35 mg/kg icaritin from day 3 to day 21 |
Applications |
Reduced frequency of CD11b+ Gr1+ myeloid-derived suppression cells (MDSCs) infiltration and downregulation of PD-L1 expression on MDSCs after icaritin treatment. This was not limited to MDSCs, as icaritin also decreased the expression of PD-L1 on neutrophils. The combination of anti-PD-1/CTLA-4 and icaritin significantly enhances antitumor ability and increases the efficacy of either treatment alone. |
References: [1]: Mo D, Zhu H, et,al. Icaritin inhibits PD-L1 expression by Targeting Protein IκB Kinase α. Eur J Immunol. 2021 Apr;51(4):978-988. doi: 10.1002/eji.202048905. Epub 2021 Feb 9. PMID: 33354776; PMCID: PMC8248075. |
Icaritin is a prenylflavonoid derivative obtained from the Epimedium genus. It has a wide range of biological and pharmacological functions, including antioxidant, anticancer and immune-enhancing[9].
Icaritin is able to inhibit PD-L1 expression in both immune cells and cancer cells, leading to its combinational in-vivo efficacy with anti-PD1 antibody in inhibition of malignant tumor growth, because Icaritin functions through immune modulation, particularly immune cells with myeloid lineage, so that THP-1 cell line was employed along with SMMC-7221 cell line[1]. The phenotype alternation induced by Abeta(25-35) could be reversed by icaritin.The neuroprotective effects of icaritin were estrogen receptor dependent due to the blocking action induced by estrogen receptor antagonist ICI 182,780 and well matched binding affinity with estrogen receptor by a receptor-ligand docking experiment[3].Icaritin, an intestinal metabolite of Epimedium-derived flavonoids (EF) enhanced osteoblastic differentiation of mesenchymal stem cells (MSCs) only under osteogenic induction conditions. Icaritin was unable to promote proliferation, migration and tube like structure formation by human umbilical vein endothelial cells (HUVECs) in vitro[5]. Icaritin inhibited AFP expression at mRNA and protein level. Icaritin abrogated murine double minute (Mdm) 2-mediated p53 ubiquitination degradation to improve the stability of p53. Icaritin-mediated decrease of AFP through Mdm2/p53 pathways inhibited HCC cellular proliferation and promoted HCC cellular apoptosis[7].
Reduced frequency of CD11b+ Gr1+ myeloid-derived suppression cells (MDSCs) infiltration and downregulation of PD-L1 expression on MDSCs after icaritin treatment. This was not limited to MDSCs, as icaritin also decreased the expression of PD-L1 on neutrophils. The combination of anti-PD-1/CTLA-4 and icaritin significantly enhances antitumor ability and increases the efficacy of either treatment alone[2].ICT treatment not only inhibited the pro-inflammatory cytokine TNF-α production and increased the anti-inflammatory cytokine IL-10 level in myocardium but also reduced the increase in the generation of superoxide content and malondialdehyde (MDA) formation and simultaneously increased the anti-oxidant capability in I/R hearts. Furthermore, ICT treatment increased Akt phosphorylation and inhibited PTEN expression in I/R hearts[4]. Icaritin suppressed tumor progression and significantly prolonged the survival of mice-bearing orthotopic and subcutaneous HCC tumors. Rather than exerting direct cytotoxic activity against tumor cells, icaritin significantly reduced the accumulation and activation of tumoral and splenic MDSCs, and increased the number and activity of cytotoxic T cells[6]. Icaritin inhibited tumor growth and induced OC cells apoptosis in patient-derived xenografts, as indicated by the tumor growth delay and increase of TUNEL-positive cells in tumor tissues. The icaritin-induced OC cell apoptosis may be associated with the activation of p53 and the suppression of Akt/mTOR pathway[8].
References:
[1]: Mo D, Zhu H, et,al. Icaritin inhibits PD-L1 expression by Targeting Protein IκB Kinase α. Eur J Immunol. 2021 Apr;51(4):978-988. doi: 10.1002/eji.202048905. Epub 2021 Feb 9. PMID: 33354776; PMCID: PMC8248075.
[2]: Hao H, Zhang Q, et,al.Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice. Eur J Immunol. 2019 Dec;49(12):2235-2244. doi: 10.1002/eji.201948225. Epub 2019 Sep 18. PMID: 31465113.
[3]: Wang Z, Zhang X, et,al. Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells via estrogen-dependent pathway. Neuroscience. 2007 Mar 30;145(3):911-22. doi: 10.1016/j.neuroscience.2006.12.059. Epub 2007 Feb 26. PMID: 17321691.
[4]: Zhang W, Xing B, et,al. Icaritin Attenuates Myocardial Ischemia and Reperfusion Injury Via Anti-Inflammatory and Anti-Oxidative Stress Effects in Rats. Am J Chin Med. 2015;43(6):1083-97. doi: 10.1142/S0192415X15500627. Epub 2015 Sep 14. PMID: 26364662.
[5]: Yao D, Xie XH, et,al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264. doi: 10.1371/journal.pone.0041264. Epub 2012 Aug 30. PMID: 22952579; PMCID: PMC3431393.
[6]: Tao H, Liu M, et,al. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation. Front Immunol. 2021 Feb 26;12:609295. doi: 10.3389/fimmu.2021.609295. PMID: 33717093; PMCID: PMC7952329.
[7]: Li H, Liu Y, et,al. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma. BMC Cancer. 2021 Mar 25;21(1):318. doi: 10.1186/s12885-021-08043-9. PMID: 33765973; PMCID: PMC7992931.
[8]: Gao L, Chen M, et,al. Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway. Life Sci. 2018 Jun 1;202:188-194. doi: 10.1016/j.lfs.2018.03.059. Epub 2018 Apr 3. PMID: 29625193.
[9]: Qian ZQ, Wang YW, et,al. Icariin prevents hypertension-induced cardiomyocyte apoptosis through the mitochondrial apoptotic pathway. Biomed Pharmacother. 2017 Apr;88:823-831. doi: 10.1016/j.biopha.2017.01.147. Epub 2017 Feb 5. PMID: 28171848.
Cas No. | 118525-40-9 | SDF | |
Canonical SMILES | O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(C/C=C(C)\C)C(O)=CC(O)=C13 | ||
Formula | C21H20O6 | M.Wt | 368.38 |
Solubility | DMSO: 14 mg/mL (38.00 mM and warming); Water: < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.7146 mL | 13.5729 mL | 27.1459 mL |
5 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL |
10 mM | 0.2715 mL | 1.3573 mL | 2.7146 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 34 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *